Rob Davis, Merck CEO
June 17, 2022 11:26 AM EDTUpdated 12:21 PM
Deals
Pharma

Up­dat­ed: Mer­ck look­ing at Seagen takeover bid in the wake of Clay Sie­gal­l's res­ig­na­tion — re­port

Paul Schloesser

Associate Editor

Mer­ck is eval­u­at­ing a po­ten­tial buy­out of em­bat­tled Seat­tle biotech Seagen, ac­cord­ing to a re­port from the Wall Street Jour­nal on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times